Industry Trend Analysis - Established Partnerships Will Support Growth Of Takeda's Vaccine Business In Asia - SEPT 2017
BMI View: Vaccine preventable diseases still remain a concern in low- and middle-income countries. As a consequence, pharmaceutical firms will increasingly focus their vaccines business on countries with less developed and evolving healthcare systems, aligning themselves with the government's push to increasing access to affordable medicines. With the aim to further establish its presence in the Asia vaccine market, Takeda Pharmaceutical announced a partnership with Biological E to develop and deliver affordable measles and pertussis vaccines in India and China.
In the absence of access to vaccines in low- and middle-income countries, where large unmet public health needs exist, substantial opportunities remain to deliver critical vaccines to those who need them. In late June 2017, Takeda Pharmaceutical announced that it will be forming a partnership with the privately-held Indian company Biological E (BE), whereby two licensing agreements to expedite the development and delivery of affordable combination vaccines will be executed, including measles and acellular pertussis vaccines. Commenting on this collaboration, in June 2017, Rahul Singhvi - chief operating officer at Takeda's Vaccine Business Unit - said, 'Access to medicines is one of Takeda's core values, and these agreements align with Takeda's strategic goals to make high-impact contributions to global public health. These two agreements along with our current vaccine pipeline underscore our global commitment to address important infectious diseases across the globe.' Takeda continues to develop innovative new medicines in key areas of therapeutic focus, such as oncology, central nervous system and specialty gastroenterology, as well as vaccines for infectious diseases with a large global burden. The revenue from emerging markets in FY2016 was +4.8% year-on-year with continued growth in the key markets of China, Russia and Brazil.
Recognizing that communicable diseases and neglected tropical diseases disproportionately affect countries with evolving healthcare systems, Takeda is collaborating with partners to expedite access to its potentially life-saving vaccine candidates. Takeda's partnership with Biological E highlights the company's interest in expanding its presence within Asia, which will help support the growth of its vaccine business.
|Measles Still A Burden In India And China|
|Total Number Of Deaths|
|Source: BMI's Disease Database|